Innovative Platform Pixlbio offers a cutting-edge platform combining iPSC-derived human models with high-throughput imaging and AI-powered phenomics, making it highly attractive for pharmaceutical companies seeking advanced predictive biology solutions for drug discovery and safety testing.

Expanding Model Range With recent expansion into cardiac and renal models, pixlbio presents opportunities to cross-sell additional tissue and disease models to existing clients and attract new customers interested in comprehensive organ-specific research.

Strong Industry Trust Trusted by eleven of the top twenty pharma companies and leading research institutions, pixlbio’s established reputation enhances its appeal as a reliable partner for high-value contract research and phenotypic screening services.

Growth Potential Operating with a revenue range of one to ten million dollars and recent funding rounds, pixlbio has the financial capacity to scale its automation, SaaS services, and model offerings, presenting upsell opportunities to larger clients and collaborations.

Digital and Global Reach Using prevalent tech stacks like Microsoft 365 and GoDaddy, along with a strong online presence via their website, pixlbio can leverage digital marketing and remote sales strategies to expand its global footprint and reach new industry segments.